Literature DB >> 26014946

A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients.

Mieke Carlier1, Jason A Roberts2, Veronique Stove3, Alain G Verstraete3, Jeffrey Lipman4, Jan J De Waele5.   

Abstract

De-escalation of empirical antibiotic therapy is often included in antimicrobial stewardship programs in critically ill patients, but differences in target attainment when antibiotics are switched are rarely considered. The primary objective of this study was to compare the fractional target attainments of contemporary dosing of empirical broad-spectrum β-lactam antibiotics and narrower-spectrum antibiotics for a number pathogens for which de-escalation may be considered. The secondary objective was to determine whether alternative dosing strategies improve target attainment. We performed a simulation study using published population pharmacokinetic (PK) studies in critically ill patients for a number of broad-spectrum β-lactam antibiotics and narrower-spectrum antibiotics. Simulations were undertaken using a data set obtained from critically ill patients with sepsis without absolute renal failure (n = 49). The probability of target attainment of antibiotic therapy for different microorganisms for which de-escalation was applied was analyzed. EUCAST MIC distribution data were used to calculate fractional target attainment. The probability that therapeutic exposure will be achieved was lower for the narrower-spectrum antibiotics with conventional dosing than for the broad-spectrum alternatives and could drastically be improved with higher dosages and different modes of administrations. For a selection of microorganisms, the probability that therapeutic exposure will be achieved was overall lower for the narrower-spectrum antibiotics using conventional dosing than for the broad-spectrum antibiotics.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26014946      PMCID: PMC4505256          DOI: 10.1128/AAC.00409-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.

Authors:  Marta Ulldemolins; Jason A Roberts; Steven C Wallis; Jordi Rello; Jeffrey Lipman
Journal:  J Antimicrob Chemother       Date:  2010-06-08       Impact factor: 5.790

2.  Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients.

Authors:  Mieke Carlier; Michaël Noë; Jan J De Waele; Veronique Stove; Alain G Verstraete; Jeffrey Lipman; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2013-06-25       Impact factor: 5.790

3.  Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter.

Authors:  Daryl D DePestel; Edward H Eiland; Katherine Lusardi; Christopher J Destache; Renée-Claude Mercier; Patrick M McDaneld; Kenneth C Lamp; Thomas J Chung; Elizabeth D Hermsen
Journal:  Clin Infect Dis       Date:  2014-10-15       Impact factor: 9.079

4.  Cefepime neurotoxicity despite renal adjusted dosing.

Authors:  Venu Gopala Reddy Gangireddy; Lauren C Mitchell; Teresa Coleman
Journal:  Scand J Infect Dis       Date:  2011-05-23

5.  Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime.

Authors:  Nicholas L Smith; Ross C Freebairn; Michael A J Park; Steven C Wallis; Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care Resusc       Date:  2012-12       Impact factor: 2.159

Review 6.  Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review.

Authors:  Sum Lam; Irving H Gomolin
Journal:  Pharmacotherapy       Date:  2006-08       Impact factor: 4.705

7.  De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.

Authors:  Djamel Mokart; Géraldine Slehofer; Jérôme Lambert; Antoine Sannini; Laurent Chow-Chine; Jean-Paul Brun; Pierre Berger; Ségolène Duran; Marion Faucher; Jean-Louis Blache; Colombe Saillard; Norbert Vey; Marc Leone
Journal:  Intensive Care Med       Date:  2014-01       Impact factor: 17.440

8.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

9.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

10.  Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?

Authors:  Mieke Carlier; Sofie Carrette; Jason A Roberts; Veronique Stove; Alain Verstraete; Eric Hoste; Pieter Depuydt; Johan Decruyenaere; Jeffrey Lipman; Steven C Wallis; Jan J De Waele
Journal:  Crit Care       Date:  2013-05-03       Impact factor: 9.097

View more
  10 in total

1.  Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.

Authors:  Liesbet De Bus; Wouter Denys; Julie Catteeuw; Bram Gadeyne; Karel Vermeulen; Jerina Boelens; Geert Claeys; Jan J De Waele; Johan Decruyenaere; Pieter O Depuydt
Journal:  Intensive Care Med       Date:  2016-03-30       Impact factor: 17.440

2.  De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome.

Authors:  Giulia la Martire; Christine Robin; Nadia Oubaya; Raphaël Lepeule; Florence Beckerich; Mathieu Leclerc; Walid Barhoumi; Andréa Toma; Cécile Pautas; Sébastien Maury; Wiem Akrout; Catherine Cordonnier-Jourdin; Vincent Fihman; Mario Venditti; Catherine Cordonnier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-07-26       Impact factor: 3.267

3.  Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.

Authors:  Jiao Xie; Qianting Yang; Xinyan Han; Yuzhu Dong; Tao Zhang; Youjia Li; Meixi Ji; Chenwei Liu; Yan Cai; Yan Wang
Journal:  Antimicrob Agents Chemother       Date:  2022-05-23       Impact factor: 5.938

4.  Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP).

Authors:  Alexis Tabah; Matteo Bassetti; Marin H Kollef; Jean-Ralph Zahar; José-Artur Paiva; Jean-Francois Timsit; Jason A Roberts; Jeroen Schouten; Helen Giamarellou; Jordi Rello; Jan De Waele; Andrew F Shorr; Marc Leone; Garyphallia Poulakou; Pieter Depuydt; Jose Garnacho-Montero
Journal:  Intensive Care Med       Date:  2019-11-28       Impact factor: 17.440

Review 5.  What's new in multidrug-resistant pathogens in the ICU?

Authors:  Gabor Zilahi; Antonio Artigas; Ignacio Martin-Loeches
Journal:  Ann Intensive Care       Date:  2016-10-06       Impact factor: 6.925

Review 6.  Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions-a viewpoint of experts.

Authors:  Jan J De Waele; Jeroen Schouten; Bojana Beovic; Alexis Tabah; Marc Leone
Journal:  Intensive Care Med       Date:  2020-02-05       Impact factor: 17.440

7.  Safety of antimicrobial de-escalation for culture-negative severe pneumonia.

Authors:  Kwon Byoung Soo; Choi Sang Ho; Koh Younsuck; Huh Jin-Won; Hong Sang-Bum; Lim Chae-Man
Journal:  J Crit Care       Date:  2019-06-28       Impact factor: 3.425

8.  Pharmacodynamics of Flucloxacillin in a Neutropenic Murine Thigh Infection Model: A Piece of the Puzzle towards Evidence-Based Dosing.

Authors:  Eveline E Roelofsen; Brenda C M de Winter; Heleen van der Spek; Susan Snijders; Birgit C P Koch; Sanne van den Berg; Anouk E Muller
Journal:  Antibiotics (Basel)       Date:  2022-08-03

9.  Bloodstream infections in critically ill patients: an expert statement.

Authors:  Jean-François Timsit; Etienne Ruppé; François Barbier; Alexis Tabah; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2020-02-11       Impact factor: 17.440

10.  Antimicrobial De-Escalation in the ICU: From Recommendations to Level of Evidence.

Authors:  Ines Lakbar; Jan J De Waele; Alexis Tabah; Sharon Einav; Ignacio Martin-Loeches; Marc Leone
Journal:  Adv Ther       Date:  2020-05-27       Impact factor: 3.845

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.